NCT00712881 2024-02-23Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast CancerTeva Branded Pharmaceutical Products R&D, Inc.Phase 2 Completed126 enrolled 16 charts
NCT02561832 2019-02-20A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast CancerAstraZenecaPhase 1 Terminated15 enrolled 8 charts